New Zealand - English - Medsafe (Medicines Safety Authority)

ipca pharma (nz) pty limited - escitalopram oxalate 6.37mg equivalent to escitalopram 5 mg;   - film coated tablet - 5 mg - active: escitalopram oxalate 6.37mg equivalent to escitalopram 5 mg   excipient: colloidal silicon dioxide croscarmellose sodium hypromellose macrogol 400 magnesium stearate microcrystalline cellulose purified talc   purified water titanium dioxide - in adults: treatment of major depression. treatment of social anxiety disorder (social phobia). treatment of generalised anxiety disorder. treatment of obsessive-compulsive disorder.

New Zealand - English - Medsafe (Medicines Safety Authority)

ipca pharma (nz) pty limited - ciprofloxacin hydrochloride 291mg equivalent ciprofloxacin 250 mg;  ;   - film coated tablet - 250 mg - active: ciprofloxacin hydrochloride 291mg equivalent ciprofloxacin 250 mg     excipient: colloidal silicon dioxide hypromellose macrogol 4000 magnesium stearate maize starch microcrystalline cellulose purified talc purified water sodium starch glycolate titanium dioxide - for complicated urinary tract infections or pyelonephritis due to e.coli in paediatric patients aged 1-17 years. the risk-benefit assessment indicates that administration of ciprofloxacin to paediatric patients is appropriate. treatment should only be initiated after careful benefit/risk evaluation, due to possible adverse events related to joints/surrounding tissues. the use of ciprofloxacin for other indications is not recommended in children.

New Zealand - English - Medsafe (Medicines Safety Authority)

ipca pharma (nz) pty limited - ciprofloxacin hydrochloride 582mg equivalent ciprofloxacin 500 mg;  ;   - film coated tablet - 500 mg - active: ciprofloxacin hydrochloride 582mg equivalent ciprofloxacin 500 mg     excipient: colloidal silicon dioxide hypromellose macrogol 4000 magnesium stearate maize starch microcrystalline cellulose purified talc purified water sodium starch glycolate titanium dioxide - for complicated urinary tract infections or pyelonephritis due to e.coli in paediatric patients aged 1-17 years. the risk-benefit assessment indicates that administration of ciprofloxacin to paediatric patients is appropriate. treatment should only be initiated after careful benefit/risk evaluation, due to possible adverse events related to joints/surrounding tissues. the use of ciprofloxacin for other indications is not recommended in children.

New Zealand - English - Medsafe (Medicines Safety Authority)

ipca pharma (nz) pty limited - ciprofloxacin hydrochloride 873mg equivalent ciprofloxacin 750 mg;  ;   - film coated tablet - 750 mg - active: ciprofloxacin hydrochloride 873mg equivalent ciprofloxacin 750 mg     excipient: colloidal silicon dioxide hypromellose macrogol 4000 magnesium stearate maize starch microcrystalline cellulose purified talc purified water sodium starch glycolate titanium dioxide - for complicated urinary tract infections or pyelonephritis due to e.coli in paediatric patients aged 1-17 years. the risk-benefit assessment indicates that administration of ciprofloxacin to paediatric patients is appropriate. treatment should only be initiated after careful benefit/risk evaluation, due to possible adverse events related to joints/surrounding tissues. the use of ciprofloxacin for other indications is not recommended in children.

Australia - English - Department of Health (Therapeutic Goods Administration)

ipca pharma (australia) pty ltd - allopurinol, quantity: 100 mg - tablet - excipient ingredients: sodium starch glycollate type a; lactose monohydrate; maize starch; stearic acid; povidone - main clinical manifestations of urate/uric acid deposition. these are gouty arthritis, skin tophi and/or renal involvement through crystal deposition or stone formation. such clinical manifestations may occur in: idiopathic gout; uric acid lithiasis; acute uric acid nephropathy; neoplastic disease and myeloproliferative disease with high cell turnover rates, in which high urate levels occur either spontaneously or after cytotoxic therapy, certain enzyme disorders which lead to overproduction of urate and involve:,? hypoxanthine guanine phosphoribosyltransferase including lesch-nyhan syndrome,,? glucose 6-phosphatase including glycogen storage disease,,? phosphoribosylpyrophosphate synthetase,,? phosphoribosylpyrophosphate amidotransferase.,allopurinol is indicated for the management of 2,8-dihydroxyadenine (2,8-dha) renal stones related to deficient activity of adenine phosphoribosyl transferase.,allopurinol is indicated for the management of recurrent mixed calcium oxalate renal stones in the presence of hyperuricosuria, when fluid, dietary and similar measures have failed.

Australia - English - Department of Health (Therapeutic Goods Administration)

ipca pharma (australia) pty ltd - allopurinol, quantity: 100 mg - tablet - excipient ingredients: povidone; sodium starch glycollate type a; lactose monohydrate; stearic acid; maize starch - main clinical manifestations of urate/uric acid deposition. these are gouty arthritis, skin tophi and/or renal involvement through crystal deposition or stone formation. such clinical manifestations may occur in: idiopathic gout; uric acid lithiasis; acute uric acid nephropathy; neoplastic disease and myeloproliferative disease with high cell turnover rates, in which high urate levels occur either spontaneously or after cytotoxic therapy, certain enzyme disorders which lead to overproduction of urate and involve:,? hypoxanthine guanine phosphoribosyltransferase including lesch-nyhan syndrome,,? glucose 6-phosphatase including glycogen storage disease,,? phosphoribosylpyrophosphate synthetase,,? phosphoribosylpyrophosphate amidotransferase.,allopurinol is indicated for the management of 2,8-dihydroxyadenine (2,8-dha) renal stones related to deficient activity of adenine phosphoribosyl transferase.,allopurinol is indicated for the management of recurrent mixed calcium oxalate renal stones in the presence of hyperuricosuria, when fluid, dietary and similar measures have failed.

Australia - English - Department of Health (Therapeutic Goods Administration)

ipca pharma (australia) pty ltd - allopurinol, quantity: 300 mg - tablet - excipient ingredients: povidone; maize starch; sodium starch glycollate type a; lactose monohydrate; stearic acid; sunset yellow fcf - main clinical manifestations of urate/uric acid deposition. these are gouty arthritis, skin tophi and/or renal involvement through crystal deposition or stone formation. such clinical manifestations may occur in: idiopathic gout; uric acid lithiasis; acute uric acid nephropathy; neoplastic disease and myeloproliferative disease with high cell turnover rates, in which high urate levels occur either spontaneously or after cytotoxic therapy, certain enzyme disorders which lead to overproduction of urate and involve:,? hypoxanthine guanine phosphoribosyltransferase including lesch-nyhan syndrome,,? glucose 6-phosphatase including glycogen storage disease,,? phosphoribosylpyrophosphate synthetase,,? phosphoribosylpyrophosphate amidotransferase.,allopurinol is indicated for the management of 2,8-dihydroxyadenine (2,8-dha) renal stones related to deficient activity of adenine phosphoribosyl transferase.,allopurinol is indicated for the management of recurrent mixed calcium oxalate renal stones in the presence of hyperuricosuria, when fluid, dietary and similar measures have failed.

Australia - English - Department of Health (Therapeutic Goods Administration)

ipca pharma (australia) pty ltd - flucloxacillin sodium monohydrate, quantity: 563.78 mg - capsule - excipient ingredients: indigo carmine; titanium dioxide; methyl hydroxybenzoate; magnesium stearate; propyl hydroxybenzoate; gelatin; purified water; propylene glycol; butan-1-ol; isopropyl alcohol; shellac; ethanol absolute; ammonia; potassium hydroxide - treatment of confirmed or suspected staphylococcal and other gram-positive coccal infections including pneumonia, osteomyelitis, skin and soft tissue and wound infections, infected burns, cellulitis.

Australia - English - Department of Health (Therapeutic Goods Administration)

ipca pharma (australia) pty ltd - flucloxacillin sodium monohydrate, quantity: 281.89 mg - capsule - excipient ingredients: gelatin; indigo carmine; propyl hydroxybenzoate; methyl hydroxybenzoate; titanium dioxide; magnesium stearate; purified water; propylene glycol; butan-1-ol; isopropyl alcohol; shellac; ethanol absolute; ammonia; potassium hydroxide - treatment of confirmed or suspected staphylococcal and other gram-positive coccal infections including pneumonia, osteomyelitis, skin and soft tissue and wound infections, infected burns, cellulitis.

Australia - English - Department of Health (Therapeutic Goods Administration)

ipca pharma (australia) pty ltd - amitriptyline hydrochloride, quantity: 50 mg - tablet - excipient ingredients: lactose monohydrate; macrogol 6000; colloidal anhydrous silica; microcrystalline cellulose; magnesium stearate; crospovidone; titanium dioxide; maize starch; purified talc; sunset yellow fcf aluminium lake; hypromellose; indigo carmine aluminium lake - for the treatment of major depression. amitriptyline 50 mg tablets are indicated only for the maintenance treatment of major depression ,nocturnal enuresis where organic pathology has been excluded.